Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

According to @godofprompt, recursive prompting is an AI technique where system outputs are fed back in as inputs to refine solutions through multiple iterations (source: @godofprompt, Dec 16, 2025).

Recursive Agents implements a three-phase iterative refinement architecture where LLM agents (instances of Classes) critique and improve their own outputs. Unlike single-pass systems, each agent ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...